Washington University School of Medicine announces a new clinical trial for COVID-19 positive patients, STOP COVID Trial. Many patients testing positive for COVID-19 initially experience mild symptoms, but then clinically deteriorate in the second week of illness.
The STOP COVID Trial tests a medication (fluvoxamine) for its anti-COVID properties for individuals ages 30 and up who have recently tested positive for COVID-19 (within 6 days), and are symptomatic. The goal of this study is to determine if a brief course of fluvoxamine can prevent the deterioration that occurs in 10-20% of patients.
In a preliminary study published in JAMA, the investigators showed fluvoxamine prevented clinical deterioration (dyspnea and hypoxia).
This is an “at-home” clinical trial – patients participate from the safety of their own home with remote monitoring.
News about about this trial were featured in CNN and the LA Times.
Adults who recently tested positive should:
- Visit us online at http://stopcovidtrial.wustl.edu
- Email us at stopcovidtrial@wustl.edu; or
- Call us at (314)747-1134
Lead investigators of the study include:
Eric Lenze, MD
Professor of Psychiatry
Caline Mattar, MD
Assistant Professor of Medicine, Infectious Disease
Angela Reiersen, MD
Associate Professor of Psychiatry